APAC Licensing Momentum Aligos secured an exclusive Greater China license for pevifoscorvir sodium with Amoytop, signaling appetite for regional partnerships. Sales opportunities include offering APAC focused development services such as clinical operations, regulatory support, and manufacturing, and identifying additional partners to commercialize HBV assets outside Greater China.

HBV Asset Monetization The company's HBV assets and related collaborations, including the ALG 170675 research program with Amoytop, suggest appetite for licensing and co development deals. Potential upsell: advisory services on deal structuring, asset valuation, and preparing assets for partner onboarding.

Commercialization Focus Leadership investments in commercialization including a new chief commercial officer indicate emphasis on market access and launch readiness. Opportunities exist to provide payer strategy, real world evidence programs, and regional commercialization planning for late stage HBV and liver disease products.

Clinical Development Services A clinical stage pipeline spanning HBV, MASH, obesity, and coronaviruses offers multiple contract research and manufacturing opportunities, including antisense oligonucleotide production, preclinical to early phase trial support, biomarker assays, and regulatory submissions.

Strategic Financing Options Funding profile with modest revenue and meaningful funding opens doors to milestone driven partnerships and non dilutive financing. Sales plays include licensing deals with upfronts and milestones, co development arrangements, and bundled development services to de risk investments for potential partners.